                         SEQUENCE LISTING

<110>  Oxford University Innovation Limited
 
<120>  ANTIBODIES

<130>  P287468WO

<140>  PCT/GB2021/05083
<141>  2021-04-01

<160>  34    

<170>  PatentIn version 3.5

<210>  1
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain of infliximab

<400>  1

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Phe Val Gly Ser Ser 
            20                  25                  30          


Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile 
        35                  40                  45              


Lys Tyr Ala Ser Glu Ser Met Ser Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Thr Val Glu Ser 
65                  70                  75                  80  


Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser His Ser Trp Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Asn Leu Glu Val Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  2
<211>  226
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain of infliximab

<400>  2

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Ile Phe Ser Asn His 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Glu Ile Arg Ser Lys Ser Ile Asn Ser Ala Thr His Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ala 
65                  70                  75                  80  


Val Tyr Leu Gln Met Thr Asp Leu Arg Thr Glu Asp Thr Gly Val Tyr 
                85                  90                  95      


Tyr Cys Ser Arg Asn Tyr Tyr Gly Ser Thr Tyr Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 
        115                 120                 125             


Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 
    130                 135                 140                 


Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 
145                 150                 155                 160 


Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 
                165                 170                 175     


Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 
            180                 185                 190         


Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 
        195                 200                 205             


Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 
    210                 215                 220                 


Lys Thr 
225     


<210>  3
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence corresponding to residues 1 to 21 of the 
       light chain of infliximab

<400>  3

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Val Ser Phe 
            20      


<210>  4
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence corresponding to residues 1 to 20 of the 
       light chain of infliximab

<400>  4

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Val Ser 
            20  


<210>  5
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence corresponding to residues 1 to 18 of the 
       light chain of infliximab

<400>  5

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg 
        


<210>  6
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence corresponding to residues 1 to 16 of the 
       light chain of infliximab

<400>  6

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


<210>  7
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DRB1*03:01

<400>  7

Asp Ile Leu Leu Thr Gln Ser Pro Ala Gly Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Val Ser Phe 
            20      


<210>  8
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DRB1*03:01

<400>  8

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Gly Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Val Ser Phe 
            20      


<210>  9
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DRB1*03:01.

<400>  9

Asp Ile Leu Leu Thr Gln Ser Pro Ala Gly Gly Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Val Ser Phe 
            20      


<210>  10
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification in the region 
       corresponding to residues 145 to 159 of the light chain of 
       infliximab

<400>  10

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 
1               5                   10                  15  


<210>  11
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DRB1*03:0

<400>  11

Lys Val Gln Trp Lys Val Gly Asn Ala Leu Gln Ser Gly Asn Ser 
1               5                   10                  15  


<210>  12
<211>  213
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain: of adalimumab

<400>  12

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn Arg Ala Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu 
    210             


<210>  13
<211>  219
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain: of adalimumab

<400>  13

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val 
    50                  55                  60                  


Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Asp Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 
        115                 120                 125             


Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 
    130                 135                 140                 


Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 
145                 150                 155                 160 


Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 
                165                 170                 175     


Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 
            180                 185                 190         


Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 
        195                 200                 205             


Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Ile 
    210                 215                 


<210>  14
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Repeat of SEQ ID NO 15 due to a numbering error.

<400>  14

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser 
            20      


<210>  15
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence corresponding to residues 1 to 21 of the 
       light chain of adalimumab

<400>  15

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser 
            20      


<210>  16
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising  a modification in the region 
       corresponding to residues 1 to 20 of  the light chain of 
       adalimumab

<400>  16

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu 
            20  


<210>  17
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification in the region 
       corresponding to residues 1 to 19 of  the light chain of 
       adalimumab

<400>  17

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg 
            


<210>  18
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  iamino acid sequence comprising a modification in the region 
       corresponding to residues 1 to 18 of  the light chain of 
       adalimumab

<400>  18

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu 
        


<210>  19
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification in the region 
       corresponding to residues 1 to 17 of  the light chain of 
       adalimumab

<400>  19

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser 
    


<210>  20
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification in the region 
       corresponding to residues 1 to 16 of  the light chain of 
       adalimumab

<400>  20

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


<210>  21
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification in the region 
       corresponding to residues 1 to 15 of  the light chain of 
       adalimumab

<400>  21

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 
1               5                   10                  15  


<210>  22
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DQA1*05:05/DQB1*03:01.

<400>  22

Glu Val Gln Leu Val Glu Ser Gly Gly Val Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser 
            20      


<210>  23
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DQA1*05:05/DQB1*03:01.

<400>  23

Glu Val Gln Leu Val Glu Ser Gly Leu Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser 
            20      


<210>  24
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DQA1*05:05/DQB1*03:01.

<400>  24

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Leu Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser 
            20      


<210>  25
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DQA1*05:05/DQB1*03:01.

<400>  25

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Leu Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser 
            20      


<210>  26
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amno acid sequence comprising a modification that inhibits 
       presentation of the antibody by DQA1*05:05/DQB1*03:01.

<400>  26

Glu Val Gln Leu Val Glu Ser Gly Leu Val Leu Leu Gln Pro Leu Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser 
            20      


<210>  27
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequece corresponding to residues 136 to 150 of the 
       heavy chain of adalimumab

<400>  27

Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 
1               5                   10                  15  


<210>  28
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DQA1*05:05/DQB1*03:01.

<400>  28

Ser Lys Ser Thr Ser Gly Val Thr Ala Ala Leu Gly Cys Leu Val 
1               5                   10                  15  


<210>  29
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DQA1*05:05/DQB1*03:01.

<400>  29

Ser Lys Ser Thr Ser Leu Val Thr Ala Ala Leu Gly Cys Leu Val 
1               5                   10                  15  


<210>  30
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DQA1*05:05/DQB1*03:01.

<400>  30

Ser Lys Ser Thr Ser Leu Val Thr Ser Ala Leu Gly Cys Leu Val 
1               5                   10                  15  


<210>  31
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DQA1*05:05/DQB1*03:01.

<400>  31

Ser Lys Ser Thr Ser Leu Val Thr Ser Ala Leu Leu Cys Leu Val 
1               5                   10                  15  


<210>  32
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DQA1*05:05/DQB1*03:01.

<400>  32

Ser Lys Ser Thr Ser Leu Val Thr Ser Leu Leu Leu Cys Leu Val 
1               5                   10                  15  


<210>  33
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence a modification that inhibits presentation of 
       the antibody by DQA1*05:05/DQB1*03:01.

<400>  33

Ser Lys Ser Leu Ser Leu Val Thr Ser Leu Leu Leu Cys Leu Val 
1               5                   10                  15  


<210>  34
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence comprising a modification that inhibits 
       presentation of the antibody by DQA1*05:05/DQB1*03:01.

<400>  34

Ser Lys Ser Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Leu Val 
1               5                   10                  15  


